MSN 611 Midterm Practice Questions With Correct
Answers
Eosinophils, |neutrophils, |and |T |cells |contain |the |type |of |histamine |receptors |referred |to |as:
a. |H1
b. |H2
c. |H3
d. |H4 |- |CORRECT |ANSWER✔✔-d. |H4
Some |1st |generation |antihistamines |are |used |to |treat
a. |as |stimulants
b. |to |prevent |motion |sickness
c. |as |anticonvulsants
d. |as |laxatives |- |CORRECT |ANSWER✔✔-b. |to |prevent |motion |sickness
2nd |generation |antihistamines |are |preferred |for |treating |which |patient |category?
a. |children
b. |women
c. |patients |with |hypertension |
d. |patients |with |insomnia |- |CORRECT |ANSWER✔✔-a. |children
Compared |to |1st |generation |antihistamines, |2nd |generation |antihistamines:
,a. |are |less |able |to |penetrate |the |blood |brain |barrier
b. |have |fewer |muscarinic |effects
c. |have |greater |anticholinergic |effects
d. |are |more |likely |to |cause |drowsiness |- |CORRECT |ANSWER✔✔-a. |are |less |able |to |penetrate |
the |blood |brain |barrier
Which |types |of |antihistamines |are |used |to |inhibit |the |secretion |of |gastric |acid |in |patients |with |
gastrointestinal |disorders?
a. |H1
b. |H2
c. |H3
d. |H4 |- |CORRECT |ANSWER✔✔-b. |H2
Under |what |two |circumstances |may |2nd |generation |antihistamines |cause |drowsiness?
a. |if |used |concurrently |with |medications |that |cause |CNS |depression |or |with |alcohol
b. |if |used |concurrently |with |medications |that |cause |CNS |depression
c. |if |they |are |taken |with |OTC |medications
d. |if |they |are |taken |with |alcohol |- |CORRECT |ANSWER✔✔-a. |if |used |concurrently |with |
medications |that |cause |CNS |depression |or |with |alcohol
Why |is |it |important |for |antiviral |compounds |to |be |able |to |discriminate |between |host |and |viral |
functions |with |a |high |degree |of |specificity?
a. |available |antiviral |agents |mainly |target |stages |in |the |viral |life |cycle
,b. |to |avoid |attacking |host |cells, |since |viruses |replicate |intracellularly |and |often |use |host |cell |
enzymes, |macromolecules, |and |organelles |to |make |their |own |particles |
c. |in |recent |years |the |demand |for |new |antiviral |strategies |has |increased |marketably |- |CORRECT
|ANSWER✔✔-b. |to |avoid |attacking |host |cells, |since |viruses |replicate |intracellularly |and |often |
use |host |cell |enzymes, |macromolecules, |and |organelles |to |make |their |own |particles
Which |of |the |following |statements |pertains |to |antimicrobial |therapy?
a. |lower |dosage |levels |of |antimicrobial |therapy |can |help |prevent |allergic |responses
b. |a |differential |diagnosis |should |indicate |whether |an |infection |is |self-limiting |
c. |self-limiting |infections |often |require |antimicrobial |therapy
d. |in |cases |of |sepsis, |laboratory |specimens |are |not |required |- |CORRECT |ANSWER✔✔-b. |a |
differential |diagnosis |should |indicate |whether |an |infection |is |self-limiting
Chose |the |correct |statement |describing |antibacterial |drugs:
a. |antibiotics |are |developed |to |have |similar |required |exposure |times |across |drug |classes
b. |Penicillinase-resistant |penicillins |are |the |agents |of |choice |for |most |staphylococcal |disease
c. |narrow |therapeutic |agents |have |a |higher |safety |tolerance |for |large |fluctuations |of |drug |in |
the |blood
d. |therapeutic |levels |of |antibacterial |agents |are |established |during |tissue |culture |studies |- |
CORRECT |ANSWER✔✔-b. |Penicillinase-resistant |penicillins |are |the |agents |of |choice |for |most |
staphylococcal |disease
The |available |modes |of |action |of |antihelmintic |drugs |is/are:
a. |excrete |in |the |intestine
b. |locally |within |the |gut |lumen |to |cause |expulsion |of |worms |from |the |GI |tract |and |systemically
|against |helminths |residing |outside |the |GI |tract
, c. |is |likely |present |in |virtually |every |mammal |residing |in |a |"natural" |habitat
d. |systemically |against |helminths |residing |outside |the |GI |tract |- |CORRECT |ANSWER✔✔-b. |
locally |within |the |gut |lumen |to |cause |expulsion |of |worms |from |the |GI |tract |and |systemically |
against |helminths |residing |outside |the |GI |tract
The |desired |response |to |antimicrobial |therapy |within |the |first |24 |to |48 |hours |includes:
a. |increased |thirst
b. |increased |sputum |production
c. |white |blood |cell |count |begins |to |normalize
d. |spike |in |temperature |- |CORRECT |ANSWER✔✔-c. |white |blood |cell |count |begins |to |normalize
Most |systemic |fungal |infections |are |acquired |via:
a. |oral-fecal |transmission
b. |inhalation
c. |direct |contact |
d. |nosocomial |transmission |- |CORRECT |ANSWER✔✔-b. |inhalation
The |ability |of |an |agent |to |continually |suppress |growth |of |an |organism |after |concentrations |
have |decreased |to |below |the |minimal |inhibitory |concentration |is |known |as:
a. |probiotic |effect
b. |postantibiotic |effect
c. |alternative |effect
d. |residual |effect |- |CORRECT |ANSWER✔✔-b. |postantibiotic |effect
Answers
Eosinophils, |neutrophils, |and |T |cells |contain |the |type |of |histamine |receptors |referred |to |as:
a. |H1
b. |H2
c. |H3
d. |H4 |- |CORRECT |ANSWER✔✔-d. |H4
Some |1st |generation |antihistamines |are |used |to |treat
a. |as |stimulants
b. |to |prevent |motion |sickness
c. |as |anticonvulsants
d. |as |laxatives |- |CORRECT |ANSWER✔✔-b. |to |prevent |motion |sickness
2nd |generation |antihistamines |are |preferred |for |treating |which |patient |category?
a. |children
b. |women
c. |patients |with |hypertension |
d. |patients |with |insomnia |- |CORRECT |ANSWER✔✔-a. |children
Compared |to |1st |generation |antihistamines, |2nd |generation |antihistamines:
,a. |are |less |able |to |penetrate |the |blood |brain |barrier
b. |have |fewer |muscarinic |effects
c. |have |greater |anticholinergic |effects
d. |are |more |likely |to |cause |drowsiness |- |CORRECT |ANSWER✔✔-a. |are |less |able |to |penetrate |
the |blood |brain |barrier
Which |types |of |antihistamines |are |used |to |inhibit |the |secretion |of |gastric |acid |in |patients |with |
gastrointestinal |disorders?
a. |H1
b. |H2
c. |H3
d. |H4 |- |CORRECT |ANSWER✔✔-b. |H2
Under |what |two |circumstances |may |2nd |generation |antihistamines |cause |drowsiness?
a. |if |used |concurrently |with |medications |that |cause |CNS |depression |or |with |alcohol
b. |if |used |concurrently |with |medications |that |cause |CNS |depression
c. |if |they |are |taken |with |OTC |medications
d. |if |they |are |taken |with |alcohol |- |CORRECT |ANSWER✔✔-a. |if |used |concurrently |with |
medications |that |cause |CNS |depression |or |with |alcohol
Why |is |it |important |for |antiviral |compounds |to |be |able |to |discriminate |between |host |and |viral |
functions |with |a |high |degree |of |specificity?
a. |available |antiviral |agents |mainly |target |stages |in |the |viral |life |cycle
,b. |to |avoid |attacking |host |cells, |since |viruses |replicate |intracellularly |and |often |use |host |cell |
enzymes, |macromolecules, |and |organelles |to |make |their |own |particles |
c. |in |recent |years |the |demand |for |new |antiviral |strategies |has |increased |marketably |- |CORRECT
|ANSWER✔✔-b. |to |avoid |attacking |host |cells, |since |viruses |replicate |intracellularly |and |often |
use |host |cell |enzymes, |macromolecules, |and |organelles |to |make |their |own |particles
Which |of |the |following |statements |pertains |to |antimicrobial |therapy?
a. |lower |dosage |levels |of |antimicrobial |therapy |can |help |prevent |allergic |responses
b. |a |differential |diagnosis |should |indicate |whether |an |infection |is |self-limiting |
c. |self-limiting |infections |often |require |antimicrobial |therapy
d. |in |cases |of |sepsis, |laboratory |specimens |are |not |required |- |CORRECT |ANSWER✔✔-b. |a |
differential |diagnosis |should |indicate |whether |an |infection |is |self-limiting
Chose |the |correct |statement |describing |antibacterial |drugs:
a. |antibiotics |are |developed |to |have |similar |required |exposure |times |across |drug |classes
b. |Penicillinase-resistant |penicillins |are |the |agents |of |choice |for |most |staphylococcal |disease
c. |narrow |therapeutic |agents |have |a |higher |safety |tolerance |for |large |fluctuations |of |drug |in |
the |blood
d. |therapeutic |levels |of |antibacterial |agents |are |established |during |tissue |culture |studies |- |
CORRECT |ANSWER✔✔-b. |Penicillinase-resistant |penicillins |are |the |agents |of |choice |for |most |
staphylococcal |disease
The |available |modes |of |action |of |antihelmintic |drugs |is/are:
a. |excrete |in |the |intestine
b. |locally |within |the |gut |lumen |to |cause |expulsion |of |worms |from |the |GI |tract |and |systemically
|against |helminths |residing |outside |the |GI |tract
, c. |is |likely |present |in |virtually |every |mammal |residing |in |a |"natural" |habitat
d. |systemically |against |helminths |residing |outside |the |GI |tract |- |CORRECT |ANSWER✔✔-b. |
locally |within |the |gut |lumen |to |cause |expulsion |of |worms |from |the |GI |tract |and |systemically |
against |helminths |residing |outside |the |GI |tract
The |desired |response |to |antimicrobial |therapy |within |the |first |24 |to |48 |hours |includes:
a. |increased |thirst
b. |increased |sputum |production
c. |white |blood |cell |count |begins |to |normalize
d. |spike |in |temperature |- |CORRECT |ANSWER✔✔-c. |white |blood |cell |count |begins |to |normalize
Most |systemic |fungal |infections |are |acquired |via:
a. |oral-fecal |transmission
b. |inhalation
c. |direct |contact |
d. |nosocomial |transmission |- |CORRECT |ANSWER✔✔-b. |inhalation
The |ability |of |an |agent |to |continually |suppress |growth |of |an |organism |after |concentrations |
have |decreased |to |below |the |minimal |inhibitory |concentration |is |known |as:
a. |probiotic |effect
b. |postantibiotic |effect
c. |alternative |effect
d. |residual |effect |- |CORRECT |ANSWER✔✔-b. |postantibiotic |effect
